Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
HemoGenyx Pharmaceuticals Plc ( (GB:HEMO) ) has issued an update.
Hemogenyx Pharmaceuticals announced that as of March 31, 2025, the company’s total issued share capital consists of 4,093,539 ordinary shares, all of which carry voting rights. This information is crucial for shareholders to determine their investment status or changes in their interest in the company’s share capital, as per the Financial Conduct Authority’s regulations.
More about HemoGenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals is a publicly traded clinical stage biopharmaceutical company headquartered in London, with US subsidiaries in New York City. The company focuses on developing new medicines and treatments for blood and autoimmune diseases, utilizing distinct product candidates and platform technologies.
YTD Price Performance: -52.16%
Average Trading Volume: 32,684
Technical Sentiment Signal: Buy
Current Market Cap: £7.93M
Find detailed analytics on HEMO stock on TipRanks’ Stock Analysis page.